Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis
Study sponsor: Abivax S.A. · ABVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-01-23Actual
Enrollment · participants40Actual
Source updated2025-11-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.